南方财经11月28日电,德琪医药-B宣布,其药物希维奥®(塞利尼索片)新增适应症被纳入国家医保目录,适用于既往接受至少两线系统性治疗的复发或难治性弥漫性大B细胞淋巴瘤(R/R DLBCL)成人患者,医保覆盖将于2025年1月1日生效。希维奥®在2024年7月获批用于治疗R/R DLBCL,成为在中国获批的第二项适应症,目前已纳入国家医保目录的两项适应症均得到覆盖。
(文章来源:南方财经网)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.